CV Sciences (OTCMKTS:CVSI)
- CEO:Joseph Dowling
CV Sciences (OTCMKTS:CVSI) Stock Price
CV Sciences (OTCMKTS:CVSI) Company Overview
CV Sciences (OTC:CVSI) operates through two segments, Specialty Pharmaceuticals, and Consumer Products. The company focuses on developing and commercialising prescription drugs utilising synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction.
The company also engages in the development, manufacture, marketing, and sale of consumer products containing Hemp-based CBD under the PlusCBD Oil name in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.
A well-run business with great management, and a solid track record, they are one of the best placed to take advantage of the massive Hemp market currently opening up across the US. The Farm Bill of 2018 has, without doubt, lifted the tides for all companies operating in the hemp-derived CBD space, and CV Sciences is primed to take advantage of this.
- Address:Suite B, 2688 South Rainbow Boulevard, Las Vegas, NV 89146, USA
CV Sciences (OTCMKTS:CVSI) Financials
The latest update from the companyClick Here
Stay updated about
Signup to get updates.
He has also held numerous senior positions including President and Chief Financial Officer of MediVas, LLC, a biotechnology company where he led day-to-day operations, drug research and development, product development and commercialization and strategic alliance building including license agreements with Pfizer, Merck, Wyeth, DSM, Guidant and Boston Scientific.
He previously graduated from the University of San Diego with a degree in Business Administration.
Michael J. Mona, JR.
He is a recognized industry leader in hemp farming operations and chemical extraction and has established a global supply chain of hemp-derived products.